ArticleEJNMMI research2026
Harmonized quantitative bone SPECT/CT parameters for risk assessment of medication-related osteonecrosis of the jaw: multicenter study.
Article in EJNMMI research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe clinical utility of harmonization of quantitative values obtained with bone single-photon computed tomography-computed tomography (SPECT/CT) for medication-related osteonecrosis of the jaw (MRONJ) classification was investigated in a Japanese multicentric study. Patients (n = 221, 255 lesions) with a clinical diagnosis of MRONJ who underwent quantitative bone SPECT/CT examinations at five hospitals were enrolled. Harmonized standard uptake values (hSUVs), including maximum (hSUVmax), peak (hSUVpeak), and mean (hSUVmean), and also metabolic bone volume (hMBV) for total volume above the threshold and total bone uptake (hTBU), calculated as hMBV×hSUVmean, were determined. One-way repeated measures analysis of variance and subsequent post hoc analysis were used for comparing harmonized quantitative values between clinical stages.
resultsThe hSUVmean values for Stage 1 (n = 71), 2 (n = 115), and 3 (n = 69) were 4.05 ± 2.25, 4.53 ± 2.65, and 5.56 ± 3.10, respectively, with those for hMBV 15.47 ± 9.77, 18.79 ± 11.83, and 18.71 ± 13.68, respectively, and for hTBU 64.03 ± 54.42, 81.46 ± 60.77, and 97.88 ± 72.07, respectively. hSUVmean and hTBU showed significant differences between clinical stages (p = 0.00089 and p = 0.00052, respectively). Post hoc analysis also indicated that the Stage 3 hSUVmean value was significantly higher than the Stage 1 or 2 value (p = 0.0037 and p = 0.028, respectively), while Stage 3 hTBU was significantly higher as compared with stage 1 and 2 (p = 0.0021 and p = 0.0049, respectively), with Stage 2 significantly higher than Stage 1 (p = 0.046).
conclusionsHarmonized SUVmean and TBU derived from quantitative bone SPECT/CT results from multicentric institutions were found to be objective and reliable indicators, and useful for MRONJ patient disease activity evaluation and stagings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.